Pro Medicus has announced a 231% increase in net profit after tax (NPAT) to $171.2 million for the six months to 31 December 2025.
This included unrealised pre-tax gains of $149.1 million from the company’s investment in 4D Medical.
Excluding these gains, underlying NPAT increased 29.7% to $67.3 million.
The healthcare infomatics company said revenue rose 28.4% to $124.8 million compared with the previous corresponding period.
Directors declared a fully franked interim dividend of 32 cents per share, up from 25 cents in the prior corresponding period, to be paid on 20 March to shareholders on record on 27 February.
Chief Executive Officer Sam Hupert said he was pleased with the record result.
“Our profits continue to grow strongly even though our biggest implementation during the period in Trinity Cohort 1 went live towards the end of October so had limited impact on the half,” he said in an ASX announcement.
“Importantly, our margins also grew, and we made more sales in this half than we used to make in a full year just two years ago.”
He said most contracts were for the full stack of Visage products – Viewer, Workflow and Archive and two also included our cardiology offering making them full stack +1, a trend we see continuing.”
The strong result was underpinned by six key implementations in the half, all of which were Cloud-based.
“We plan to complete another seven go-lives before the end of the financial year including three more Trinity cohorts,” Hupert said.
“Revenues will flow as each implementation comes on stream, building the base for a stronger second half and beyond”
Pro Medicus shares (ASX: PME) shares had closed $1.81 (1.08%) higher at $169.47 on Wednesday, capitalising the company at $17.70 billion.
